Compare Stocks: XERS, AMRX, LQDA, and DFTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$19.77 -0.2%	$18.07	$9.56 ▼ $21.17	$6.31B	1.24	2.42 million shs	2.52 million shs
DFTX Definium Therapeutics	$36.17 -1.5%	$41.59	$9.62 ▼ $49.70	$4.86B	2.23	2.19 million shs	2.68 million shs
LQDA Liquidia	$68.43 -3.6%	$75.40	$21.15 ▼ $93.61	$6.13B	0.53	1.16 million shs	967,315 shs
XERS Xeris Biopharma	$9.10 +1.7%	$8.36	$5.25 ▼ $10.08	$1.66B	0.7	1.83 million shs	1.55 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	0.00%	+5.67%	+9.77%	+14.74%	+103.60%
DFTX Definium Therapeutics	0.00%	-6.80%	-17.46%	-19.53%	+268.33%
LQDA Liquidia	0.00%	+2.32%	-2.16%	-12.46%	+211.90%
XERS Xeris Biopharma	0.00%	+10.98%	+5.81%	+18.34%	+13.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$19.77 -0.2%	$18.07	$9.56 ▼ $21.17	$6.31B	1.24	2.42 million shs	2.52 million shs
DFTX Definium Therapeutics	$36.17 -1.5%	$41.59	$9.62 ▼ $49.70	$4.86B	2.23	2.19 million shs	2.68 million shs
LQDA Liquidia	$68.43 -3.6%	$75.40	$21.15 ▼ $93.61	$6.13B	0.53	1.16 million shs	967,315 shs
XERS Xeris Biopharma	$9.10 +1.7%	$8.36	$5.25 ▼ $10.08	$1.66B	0.7	1.83 million shs	1.55 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	0.00%	+5.67%	+9.77%	+14.74%	+103.60%
DFTX Definium Therapeutics	0.00%	-6.80%	-17.46%	-19.53%	+268.33%
LQDA Liquidia	0.00%	+2.32%	-2.16%	-12.46%	+211.90%
XERS Xeris Biopharma	0.00%	+10.98%	+5.81%	+18.34%	+13.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRX Amneal Pharmaceuticals	2.90	Moderate Buy	$21.00	6.22% Upside
DFTX Definium Therapeutics	3.00	Buy	$64.88	79.36% Upside
LQDA Liquidia	2.45	Hold	$98.08	43.33% Upside
XERS Xeris Biopharma	2.43	Hold	$12.80	40.66% Upside

Current Analyst Ratings Breakdown

Latest XERS, AMRX, LQDA, and DFTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	AMRX Amneal Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
9/22/2026	LQDA Liquidia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C)
9/22/2026	LQDA Liquidia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
9/17/2026	AMRX Amneal Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$16.00 ➝ $20.00
9/15/2026	DFTX Definium Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$64.00 ➝ $78.00
9/15/2026	DFTX Definium Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$70.00
9/15/2026	DFTX Definium Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$75.00 ➝ $79.00
9/14/2026	DFTX Definium Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$75.00
9/14/2026	DFTX Definium Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$70.00
9/14/2026	DFTX Definium Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$66.00
9/11/2026	DFTX Definium Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$66.00

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRX Amneal Pharmaceuticals	$3.02B	2.09	$1.56 per share	12.66	($0.23) per share	-85.96
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	$3.36 per share	N/A
LQDA Liquidia	$450.91M	13.58	N/A	N/A	$0.51 per share	134.18
XERS Xeris Biopharma	$335.41M	4.95	$0.10 per share	90.85	$0.08 per share	113.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRX Amneal Pharmaceuticals	$72.06M	$0.49	40.35	18.31	2.34	5.05%	-584.46%	7.78%	N/A
DFTX Definium Therapeutics	-$183.79M	-$3.43	N/A	N/A	N/A	N/A	-84.01%	-63.66%	N/A
LQDA Liquidia	-$68.92M	$1.37	49.95	15.62	N/A	30.74%	149.65%	36.30%	11/2/2026 (Estimated)
XERS Xeris Biopharma	$550K	-$0.11	N/A	30.33	N/A	-5.12%	338.21%	3.50%	11/5/2026 (Estimated)

Latest XERS, AMRX, LQDA, and DFTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/6/2026	Q2 2026	DFTX Definium Therapeutics	-$0.55	-$1.44	-$0.89	-$1.44	N/A	N/A
8/6/2026	Q2 2026	XERS Xeris Biopharma	$0.0121	-$0.18	-$0.1921	-$0.18	$90.13 million	$92.10 million
7/30/2026	Q2 2026	AMRX Amneal Pharmaceuticals	$0.24	$0.30	+$0.06	$0.18	N/A	$796.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRX Amneal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DFTX Definium Therapeutics	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRX Amneal Pharmaceuticals	77.65	2.20	1.44
DFTX Definium Therapeutics	0.04	6.95	6.95
LQDA Liquidia	0.63	2.31	2.12
XERS Xeris Biopharma	17.00	1.45	1.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRX Amneal Pharmaceuticals	31.82%
DFTX Definium Therapeutics	27.91%
LQDA Liquidia	64.54%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
AMRX Amneal Pharmaceuticals	17.30%
DFTX Definium Therapeutics	2.40%
LQDA Liquidia	25.60%
XERS Xeris Biopharma	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRX Amneal Pharmaceuticals	8,500	319.35 million	264.11 million	Optionable
DFTX Definium Therapeutics	40	134.37 million	131.14 million	Optionable
LQDA Liquidia	216	89.51 million	66.60 million	Optionable
XERS Xeris Biopharma	435	182.32 million	174.39 million	Optionable

XERS, AMRX, LQDA, and DFTX Headlines

Recent News About These Companies

1,397,050 Shares of Xeris Biopharma Holdings, Inc. $XERS Acquired by Bank of America Corp DE

3 hours ago | marketbeat.com

Corient Private Wealth LP Acquires 184,126 Shares of Xeris Biopharma Holdings, Inc. $XERS

September 26 at 3:05 AM | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of "Hold" by Analysts

September 21, 2026 | marketbeat.com

Xeris Biopharma stock gains on higher targets and August results

September 19, 2026 | ad-hoc-news.deA

Xeris Biopharma (NASDAQ:XERS) Upgraded to "Buy" at Wall Street Zen

September 19, 2026 | americanbankingnews.com

Wall Street Zen Upgrades Xeris Biopharma (NASDAQ:XERS) to Buy

September 19, 2026 | marketbeat.com

Xeris Biopharma Holdings stock gains after strong Q2 revenue growth

September 18, 2026 | ad-hoc-news.deA

Squarepoint Ops LLC Has $2.90 Million Holdings in Xeris Biopharma Holdings, Inc. $XERS

September 14, 2026 | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy - Slideshow

September 11, 2026 | seekingalpha.com

Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript

September 9, 2026 | seekingalpha.com

Xeris Biopharma (NASDAQ:XERS) Trading Down 8.7% - Time to Sell?

September 9, 2026 | marketbeat.com

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

September 9, 2026 | finance.yahoo.com

Wellington Management Group LLP Acquires 193,749 Shares of Xeris Biopharma Holdings, Inc. $XERS

September 7, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $3.87 Million in Xeris Biopharma Holdings, Inc. $XERS

September 6, 2026 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Stock Rating Lowered by Wall Street Zen

September 5, 2026 | marketbeat.com

Corient Private Wealth LP Invests $1.46 Million in Xeris Biopharma Holdings, Inc. $XERS

September 4, 2026 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Insider Sells 5,000 Shares

September 2, 2026 | insidertrades.com

Jupiter Topco LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERS

September 2, 2026 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Insider Steven Pieper Sells 5,000 Shares

September 1, 2026 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Insider Sells $127,350.00 in Stock

September 1, 2026 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Insider Sells 16,666 Shares

September 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS, AMRX, LQDA, and DFTX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

$19.77 -0.04 (-0.20%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$19.87 +0.10 (+0.50%)

As of 09/25/2026 07:59 PM Eastern

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Definium Therapeutics NASDAQ:DFTX

$36.17 -0.56 (-1.52%)

As of 09/25/2026 04:00 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Liquidia NASDAQ:LQDA

$68.43 -2.52 (-3.55%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$69.78 +1.35 (+1.98%)

As of 09/25/2026 07:30 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Xeris Biopharma NASDAQ:XERS

$9.10 +0.15 (+1.68%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$9.11 +0.01 (+0.15%)

As of 09/25/2026 07:30 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XERS, AMRX, LQDA, and DFTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XERS, AMRX, LQDA, and DFTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XERS, AMRX, LQDA, and DFTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS, AMRX, LQDA, and DFTX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Definium Therapeutics NASDAQ:DFTX

Liquidia NASDAQ:LQDA

Xeris Biopharma NASDAQ:XERS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XERS, AMRX, LQDA, and DFTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XERS, AMRX, LQDA, and DFTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XERS, AMRX, LQDA, and DFTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS, AMRX, LQDA, and DFTX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Definium Therapeutics NASDAQ:DFTX

Liquidia NASDAQ:LQDA

Xeris Biopharma NASDAQ:XERS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools